Issue of Securities Following General Meeting Approval
Filed with ASX · · 1 page · English
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Ethics Approval for Phase 2 Clinical Trial of IRX-211
- Sep24 Appendix 4C Cash Flow Report
- Sep24 Quarterly Activities Report
- $38.5m Funding to Fully Fund Clinical Development Plans
- Issue of Shares to CEO in Lieu of Accrued Salary
Later from Nexalis Therapeutics
- Shareholder Update
- Dec24 Appendix 4C Cash Flow Report
- Dec24 Quarterly Activities Report
- Updated Dec24 Quarterly Activities Report
- Study Order Executed for Phase 2 BTcP Trial
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics